Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP

Shanta Boddapati, Yona Levites, Vick Suryadi, Srinath Kasturirangan, Michael Sierks

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Misfolding and aggregation of amyloid-β (Aβ) is an important early event in the pathogenesis of Alzheimer's disease. Aβ is produced by sequential proteolysis of the amyloid-β protein precursor (AβPP) by β- and γ-secretases. A third protease, α-secretase, cleaves AβPP in the middle of the Aβ sequence precluding formation of Aβ. The levels of Aβ generated from AβPP can therefore be controlled by tailoring activity of these proteases toward AβPP. We previously showed that β-secretase proteolysis of AβPP could be selectively inhibited using the single chain antibody fragment (scFv) iBSEC1, which blocks the cleavage site on AβPP, and α-secretase proteolysis of AβPP could be selectively enhanced using a proteolytic scFv (Asec1A) engineered to have α-secretase-like activity. Here we show that DIA10D, a novel tandem bispecific scFv combining iBSEC1 with the ASec1A can control amyloidogenic processing of AβPP by simultaneously inhibiting β-secretase and increasing α-secretase processing of AβPP. When expressed in H4 (neuroglioma) cells overexpressing AβPP, DIA10D potently reduces levels of extracellular Aβ by around 50% while also increasing levels of neuroprotective sAβPPα. DIA10D activity has been designed to selectively target AβPP, so this modulation of AβPP processing should not affect endogenous activity of α-and β-secretases towards other substrates.

Original languageEnglish (US)
Pages (from-to)961-969
Number of pages9
JournalJournal of Alzheimer's Disease
Volume28
Issue number4
DOIs
StatePublished - 2012

Fingerprint

Single-Chain Antibodies
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Proteolysis
Peptide Hydrolases
Immunoglobulin Fragments
Amyloid
Alzheimer Disease

Keywords

  • α-secretase
  • β-secretase
  • AβPP processing
  • bispecific tandem scFv

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP. / Boddapati, Shanta; Levites, Yona; Suryadi, Vick; Kasturirangan, Srinath; Sierks, Michael.

In: Journal of Alzheimer's Disease, Vol. 28, No. 4, 2012, p. 961-969.

Research output: Contribution to journalArticle

Boddapati, Shanta ; Levites, Yona ; Suryadi, Vick ; Kasturirangan, Srinath ; Sierks, Michael. / Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP. In: Journal of Alzheimer's Disease. 2012 ; Vol. 28, No. 4. pp. 961-969.
@article{b3b212e4c5044357bac7c707b4ea7994,
title = "Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP",
abstract = "Misfolding and aggregation of amyloid-β (Aβ) is an important early event in the pathogenesis of Alzheimer's disease. Aβ is produced by sequential proteolysis of the amyloid-β protein precursor (AβPP) by β- and γ-secretases. A third protease, α-secretase, cleaves AβPP in the middle of the Aβ sequence precluding formation of Aβ. The levels of Aβ generated from AβPP can therefore be controlled by tailoring activity of these proteases toward AβPP. We previously showed that β-secretase proteolysis of AβPP could be selectively inhibited using the single chain antibody fragment (scFv) iBSEC1, which blocks the cleavage site on AβPP, and α-secretase proteolysis of AβPP could be selectively enhanced using a proteolytic scFv (Asec1A) engineered to have α-secretase-like activity. Here we show that DIA10D, a novel tandem bispecific scFv combining iBSEC1 with the ASec1A can control amyloidogenic processing of AβPP by simultaneously inhibiting β-secretase and increasing α-secretase processing of AβPP. When expressed in H4 (neuroglioma) cells overexpressing AβPP, DIA10D potently reduces levels of extracellular Aβ by around 50{\%} while also increasing levels of neuroprotective sAβPPα. DIA10D activity has been designed to selectively target AβPP, so this modulation of AβPP processing should not affect endogenous activity of α-and β-secretases towards other substrates.",
keywords = "α-secretase, β-secretase, AβPP processing, bispecific tandem scFv",
author = "Shanta Boddapati and Yona Levites and Vick Suryadi and Srinath Kasturirangan and Michael Sierks",
year = "2012",
doi = "10.3233/JAD-2011-111196",
language = "English (US)",
volume = "28",
pages = "961--969",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP

AU - Boddapati, Shanta

AU - Levites, Yona

AU - Suryadi, Vick

AU - Kasturirangan, Srinath

AU - Sierks, Michael

PY - 2012

Y1 - 2012

N2 - Misfolding and aggregation of amyloid-β (Aβ) is an important early event in the pathogenesis of Alzheimer's disease. Aβ is produced by sequential proteolysis of the amyloid-β protein precursor (AβPP) by β- and γ-secretases. A third protease, α-secretase, cleaves AβPP in the middle of the Aβ sequence precluding formation of Aβ. The levels of Aβ generated from AβPP can therefore be controlled by tailoring activity of these proteases toward AβPP. We previously showed that β-secretase proteolysis of AβPP could be selectively inhibited using the single chain antibody fragment (scFv) iBSEC1, which blocks the cleavage site on AβPP, and α-secretase proteolysis of AβPP could be selectively enhanced using a proteolytic scFv (Asec1A) engineered to have α-secretase-like activity. Here we show that DIA10D, a novel tandem bispecific scFv combining iBSEC1 with the ASec1A can control amyloidogenic processing of AβPP by simultaneously inhibiting β-secretase and increasing α-secretase processing of AβPP. When expressed in H4 (neuroglioma) cells overexpressing AβPP, DIA10D potently reduces levels of extracellular Aβ by around 50% while also increasing levels of neuroprotective sAβPPα. DIA10D activity has been designed to selectively target AβPP, so this modulation of AβPP processing should not affect endogenous activity of α-and β-secretases towards other substrates.

AB - Misfolding and aggregation of amyloid-β (Aβ) is an important early event in the pathogenesis of Alzheimer's disease. Aβ is produced by sequential proteolysis of the amyloid-β protein precursor (AβPP) by β- and γ-secretases. A third protease, α-secretase, cleaves AβPP in the middle of the Aβ sequence precluding formation of Aβ. The levels of Aβ generated from AβPP can therefore be controlled by tailoring activity of these proteases toward AβPP. We previously showed that β-secretase proteolysis of AβPP could be selectively inhibited using the single chain antibody fragment (scFv) iBSEC1, which blocks the cleavage site on AβPP, and α-secretase proteolysis of AβPP could be selectively enhanced using a proteolytic scFv (Asec1A) engineered to have α-secretase-like activity. Here we show that DIA10D, a novel tandem bispecific scFv combining iBSEC1 with the ASec1A can control amyloidogenic processing of AβPP by simultaneously inhibiting β-secretase and increasing α-secretase processing of AβPP. When expressed in H4 (neuroglioma) cells overexpressing AβPP, DIA10D potently reduces levels of extracellular Aβ by around 50% while also increasing levels of neuroprotective sAβPPα. DIA10D activity has been designed to selectively target AβPP, so this modulation of AβPP processing should not affect endogenous activity of α-and β-secretases towards other substrates.

KW - α-secretase

KW - β-secretase

KW - AβPP processing

KW - bispecific tandem scFv

UR - http://www.scopus.com/inward/record.url?scp=84858052507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858052507&partnerID=8YFLogxK

U2 - 10.3233/JAD-2011-111196

DO - 10.3233/JAD-2011-111196

M3 - Article

C2 - 22156046

AN - SCOPUS:84858052507

VL - 28

SP - 961

EP - 969

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -